Pfizer-BioNTech updated COVID shot shows strong immune response in high-risk groups
A total of 100 adults were enrolled in the trial
(Reuters): Pfizer (PFE.N), opens new tab and partner BioNTech (22UAy.DE), opens new tab said on Monday their updated COVID-19 vaccine showed an increased immune response in adults aged 65 and older as well as those aged 18 through 64 with at least one underlying risk condition.
Preliminary data from an ongoing late-stage trial showed at least a four-fold increase in levels of LP.8.1-neutralizing antibody after receiving the updated COVID-19 vaccine, the companies said.
A total of 100 adults were enrolled in the trial.
This study was conducted to provide additional information about immunological effects of the vaccine and is not intended to replace the post-marketing commitments requested by the US health regulator.
Taliban must choose between Pakistan, terror groups: sources
- 6 minutes ago
Rising fuel prices lash airline sector as Iran conflict widens
- 11 minutes ago
Gold prices plunge in Pakistan, global markets
- 32 minutes ago
Pakistan Army continuing action against Afghan Taliban, Fitna Al Khawarij
- 5 hours ago
The AI industry’s civil war
- 15 hours ago
The US military reportedly shot down a CBP drone with a laser
- 8 hours ago
The Supreme Court’s Republicans just seized the most dangerous power in constitutional law
- 15 hours ago
WHO says has it has verified 13 health attacks in Iran
- 43 minutes ago
T20 World Cup: India set 254-run target for England in second semi-final
- 20 minutes ago
Iran FM says US will ‘bitterly regret’ precedent set by sinking ship
- 6 hours ago
Death anniversary of legendary actor Qavi Khan observed today
- 6 hours ago
NASA is pushing back its plans for a Moon landing
- 8 hours ago
